Mechanisms and clinical implications of renal drug excretion.
about
Renal drug transporters and their significance in drug-drug interactionsCompetitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecidQuantitative structure-pharmacokinetic relationships for the prediction of renal clearance in humansPodocyte-specific expression of organic cation transporter PMAT: implication in puromycin aminonucleoside nephrotoxicity.Human pharmacogenomic variations and their implications for antifungal efficacy.Short-term beneficial effects of methylene blue on kidney damage in septic shock patients.Drug-drug interactions involving membrane transporters in the human kidney.Use of in vitro transporter assays to understand hepatic and renal disposition of new drug candidates.Prediction of human pharmacokinetics - renal metabolic and excretion clearance.A quantitative threshold for high/low extent of urinary excretion of compounds in humans.Inhibition of flucloxacillin tubular renal secretion by piperacillinModeling kinetics of subcellular disposition of chemicals.Medications in the kidney.Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state.Pharmacokinetics of intravenous finafloxacin in healthy volunteers.A pH-responsive carboxymethyl dextran-based conjugate as a carrier of docetaxel for cancer therapy.Evaluation and Quantitative Prediction of Renal Transporter-Mediated Drug-Drug Interactions.Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).Binding of perfluorooctanoic acid to rat liver-form and kidney-form alpha2u-globulins.The in vivo disposition and in vitro transmembrane transport of two model radiometabolites of DOTA-conjugated receptor-specific peptides labelled with (177) Lu.Uremic Toxins Induce ET-1 Release by Human Proximal Tubule Cells, which Regulates Organic Cation Uptake Time-Dependently.Impact of Substrate-Dependent Inhibition on Renal Organic Cation Transporters hOCT2 and hMATE1/2-K-Mediated Drug Transport and Intracellular Accumulation.Renal elimination of a novel and potent alphavbeta3 integrin antagonist in animals.Identification of metabolites of [14C]zonampanel, an a-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, following intravenous infusion in healthy volunteers.Pharmacokinetics and Disposition of the Thiouracil Derivative PF-06282999, an Orally Bioavailable, Irreversible Inactivator of Myeloperoxidase Enzyme, Across Animals and Humans.Application of the isolated perfused rat kidney model to assess gender effects on drug excretion.Transporters in Drug Discovery
P2860
Q28071292-FE7AB558-4211-4791-9C41-B667ADD624BAQ33668223-651C81E2-B3E7-4CF2-A124-0772B77C367FQ34785494-A9599EE6-8538-41EA-B69C-BF1B02B7F13DQ34974839-C98FA73E-C306-4296-9254-C3D38AE17374Q35070838-618CDAA6-60B2-44D5-ACA1-BEF93C2E6E7AQ36432124-1971136B-D161-4B95-9341-770417DA9287Q36543091-0312599B-8439-4CF8-AE3E-59D438F9EC5AQ36544962-C9828779-A664-4CAF-9AA4-18DF999D6E81Q36988426-27DD7DA5-442F-4D75-BEB4-0E3E2D67FA2DQ37116050-2735C143-B221-4E12-9434-B33A440AB4FCQ37142437-82FDC38E-7801-4917-B6F5-8FC9570879F8Q37194304-0C1A3964-E55B-4964-B1EB-5296D1CBE555Q37198832-1A36FB03-A043-484B-9A3A-F8040A889D0CQ37740151-84561F66-164A-409E-AD62-CB035E9DEE16Q38636236-B430D0D6-50DB-4ECF-B8EC-282D5E5D44D4Q38810269-5E5CFC7D-0ED1-447B-B297-FDDB9E7E954FQ38844658-2D7D4D94-C567-4D73-8D7C-6A12ACFA54DBQ38855314-127FBFB4-6915-4BAE-949C-D6FA5A08A64EQ39129370-18FB3DC6-2F8C-491F-A8C9-75E8BCA306C0Q40364919-FABA1B55-FDB1-4B4E-BF07-D207B0223A2AQ41617023-AEE6D3E9-DF52-49C2-9285-045693B875ABQ42500726-C116361D-A946-45FE-9ACA-3C9EF68AD1ACQ46413703-2F11A23F-1A6A-4D81-87B4-5118F38E0071Q46601137-BEBA795C-C26F-47F8-95DA-250232267918Q46633556-C5D4C4B0-5544-4BD8-83CE-0D9D02F1F24DQ51787633-FA06F439-33C4-4A5E-A5E2-5D44952CABA4Q57684264-D18BBF8C-455F-42D3-98ED-4AC5E4BEDA69
P2860
Mechanisms and clinical implications of renal drug excretion.
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Mechanisms and clinical implications of renal drug excretion.
@ast
Mechanisms and clinical implications of renal drug excretion.
@en
Mechanisms and clinical implications of renal drug excretion.
@nl
type
label
Mechanisms and clinical implications of renal drug excretion.
@ast
Mechanisms and clinical implications of renal drug excretion.
@en
Mechanisms and clinical implications of renal drug excretion.
@nl
prefLabel
Mechanisms and clinical implications of renal drug excretion.
@ast
Mechanisms and clinical implications of renal drug excretion.
@en
Mechanisms and clinical implications of renal drug excretion.
@nl
P2860
P356
P1476
Mechanisms and clinical implications of renal drug excretion.
@en
P2093
Masereeuw R
P2860
P304
P356
10.1081/DMR-120000654
P407
P577
2001-08-01T00:00:00Z